title: Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
abstract: The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA (mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.
authors.affiliation: Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire, Hôtel Dieu, Nantes, France;
authors.forename: Céline
authors.initials: C
authors.lastname: Bossard
authors.affiliation: Swiss Institute of Bioinformatics, Bȃtiment Genopode, Lausanne, Switzerland;
authors.forename: Maria Pamela
authors.initials: MP
authors.lastname: Dobay
authors.affiliation: Département de Pathologie, Hôpital Pessac, Bordeaux, France;
authors.forename: Marie
authors.initials: M
authors.lastname: Parrens
authors.affiliation: Département de Pathologie, Hôpital Purpan, Toulouse, France;
authors.forename: Laurence
authors.initials: L
authors.lastname: Lamant
authors.affiliation: Swiss Institute of Bioinformatics, Bȃtiment Genopode, Lausanne, Switzerland;
authors.forename: Edoardo
authors.initials: E
authors.lastname: Missiaglia
authors.affiliation: Unité Hémopathies Lymphoïdes, Groupe Henri Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France;
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.affiliation: Service d'Anatomie et Cytologie Pathologiques, Hôpital Avicenne, Bobigny, France;
authors.forename: Antoine
authors.initials: A
authors.lastname: Martin
authors.affiliation: Département d'Anatomie Pathologique, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Paris, France;
authors.forename: Bettina
authors.initials: B
authors.lastname: Fabiani
authors.affiliation: Service d'Hématologie, Hôpital Necker, Assistance Publique - Hôpitaux de Paris, Paris, France;
authors.forename: Richard
authors.initials: R
authors.lastname: Delarue
authors.affiliation: Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Université d'Auvergne, Inserm Centre d'Investigation Clinique 501, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France;
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Swiss Institute of Bioinformatics, Bȃtiment Genopode, Lausanne, Switzerland; Ludwig Center for Cancer Research, and Oncology Department, University of Lausanne, Lausanne, Switzerland;
authors.forename: Mauro
authors.initials: M
authors.lastname: Delorenzi
authors.affiliation: Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France; Inserm U955, Créteil, France; Université Paris Est, Créteil, France; and.
authors.forename: Philippe
authors.initials: P
authors.lastname: Gaulard
authors.affiliation: Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: Laurence
authors.initials: L
authors.lastname: de Leval
mesh_terms: D000079963:Brentuximab Vedotin; D016903:Drug Monitoring / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007150:Immunohistochemistry / Q000379:methods* / Q000592:standards; D017730:Ki-1 Antigen / Q000235:genetics* / Q000378:metabolism*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D015203:Reproducibility of Results
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D012333:RNA, Messenger; D000079963:Brentuximab Vedotin